June 8th, 2020 - Sarepta Therapeutics has announced positive data for the SRP-9003 gene therapy trial for the treatment of type 2E Limb girdle muscular dystrophy. The release reports positive data at 3 months of high-dose treatment. Furthermore, in patients treated at low doses there are still improvements even after 9 months of treatment.
Other press releases:
New data gives hope for Limb Girdle Muscular Dystrophy gene therapy - Patient Worthy
SRP-9003 gene therapy for LGMD2E shows benefits after 1 year - Muscular dystrophy news today